Eli Lilly and Co LLY:NYSE

Earnings Announcement Next Earnings date is expected on 02/03/2022
Last Price$236.70Cboe Real-Time Last Sale as of 3:10PM ET 1/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-1.16(0.49%)
Bid (Size)$236.52 (2)
Ask (Size)$236.79 (200)
Day Low / High$236.15 - 243.24
Volume1.4 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 01/27/2022


Eli Lilly and Co ( NYSE )

Price: $236.70
Change: -1.16 (0.49%)
Volume: 1.4 M
3:10PM ET 1/27/2022

Abbvie Inc ( NYSE )

Price: $136.58
Change: +2.35 (1.75%)
Volume: 6.7 M
3:10PM ET 1/27/2022

Merck & Co Inc ( NYSE )

Price: $81.15
Change: +2.01 (2.54%)
Volume: 12.0 M
3:10PM ET 1/27/2022

Pfizer Inc ( NYSE )

Price: $53.69
Change: +1.08 (2.04%)
Volume: 24.9 M
3:10PM ET 1/27/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $63.99
Change: +1.75 (2.81%)
Volume: 11.5 M
3:10PM ET 1/27/2022

Read more news Recent News

Market Chatter: FDA to Restrict Monoclonal Antibodies Manufactured by Eli Lilly, Regeneron Pharmaceuticals
1:00PM ET 1/24/2022 MT Newswires

The Food and Drug Administration is expected to restrict the use of two monoclonal antibodies, which will halt distribution of the therapies produced by...

Morgan Stanley Adjusts Eli Lilly and Co.'s Price Target to $272 from $275, Keeps Overweight Rating
11:08AM ET 1/24/2022 MT Newswires

Eli Lilly and Co. (LLY) has an average rating of outperform and price targets ranging from $202 to $335, according to analysts polled by Capital IQ. (MT...

DZ Bank Upgrades Eli Lilly and Co. to Buy From Hold; Price Target is $291
6:41AM ET 1/21/2022 MT Newswires

Eli Lilly and Co. (LLY) has an average rating of outperform and price targets ranging from $202 to $335, according to analysts polled by Capital IQ. (MT...

Evotec, Eli Lilly to Collaborate on Treatments for Metabolic Diseases
4:56AM ET 1/18/2022 MT Newswires

Evotec (EVO) on Tuesday said that has entered into a three-year drug discovery deal with Eli Lilly (LLY) to develop treatments for metabolic diseases with...

Company Profile

Business DescriptionEli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN. View company web site for more details
AddressLilly Corporate Center
Indianapolis, Indiana 46285
Number of Employees38,680
Recent SEC Filing01/20/20224
Chairman, President & Chief Executive OfficerDavid A. Ricks
Chief Financial Officer & Senior Vice PresidentAnat Ashkenazi
Chief Medical Officer & VP-Global MedicalTimothy J. Garnett
Chief Scientific Officer & Senior Vice PresidentDaniel M. Skovronsky

Company Highlights

Price Open$239.98
Previous Close$237.86
52 Week Range$178.58 - 283.90
Market Capitalization$226.4 B
Shares Outstanding956.6 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$0.98 / 1.65%
Dividend Ex-Date02/14/2022
Dividend Pay-Date03/10/2022
Dividend Yield 5 Year Average2.03%
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings37.05
Earnings per Share$7.73
Beta vs. S&P 500N/A
Revenue$24.6 B
Net Profit Margin21.52%
Return on Equity89.33%

Analyst Ratings as of 01/19/2022

Consensus RecommendationConsensus Icon
Powered by Factset